About this trial
Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the application value in the accurate staging of liver cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.
Age > 18 years.
Patients suspected of having liver cancer.
Patients who have signed the informed consent form.
Disqualifiers
Severe cardiac, pulmonary, or renal insufficiency.
Allergy to iodine-based contrast agents.
Inability to cooperate with the CT examination.
Poor image quality of the Quark Spectral CT scan.
Trial design
Single group
Treatments tested in this trial
To explore the value of spectral CT in the diagnosis and treatment of liver cancer
Diagnostic testThe CT scan is part of the standard treatment protocol.
Treatment groups
Trial outcomes
Primary outcomes
Pathological TNM staging
Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: